Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 302 matching trials from the live ClinicalTrials.gov search.
Conditions
Diastolic Heart Failure, Diastolic Dysfunction
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Decatur, Georgia
Conditions
Congestive Heart Failure
Interventions
blood volume measurement, venous plethysmography
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Exercise Cardiovascular Magnetic Resonance
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Heart Failure, Diastolic
Interventions
Exercise training
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
60 Years to 90 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Diastolic Heart Failure
Interventions
alagebrium, placebo
Drug
Lead sponsor
Synvista Therapeutics, Inc
Industry
Eligibility
50 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
30
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 27 more
Terminated Not applicable Interventional Results available

Global Prevalence of ATTR-CM in Participants With HFpEF

NCT04424914
Conditions
Transthyretin Amyloid Cardiomyopathy, Heart Failure With Preserved Ejection Fraction
Interventions
Scintigraphy
Diagnostic Test
Lead sponsor
Pfizer
Industry
Eligibility
60 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
22
States / cities
Fairhope, Alabama • Huntsville, Alabama • Miami, Florida + 11 more
Conditions
Heart Failure
Interventions
Potassium Nitrate (KNO3), Potassium Chloride (KCl)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 90 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
3
States / cities
Evanston, Illinois • Philadelphia, Pennsylvania
Conditions
Heart Failure
Interventions
Placebo, Sildenafil
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
9
States / cities
Phoenix, Arizona • Atlanta, Georgia • Boston, Massachusetts + 6 more
Conditions
Atrial Fibrillation (AF), Atrial Fibrillation (Paroxysmal), Persistent Atrial Fibrillation, Heart Failure With Preserved Ejection Fraction (HFPEF)
Interventions
progressive resistance training, combined aerobic + resistance training
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
60 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
Tirzepatide, Placebo
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years and older
Enrollment
731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
54
States / cities
Huntsville, Alabama • Beverly Hills, California • Covina, California + 51 more
Conditions
Atrial Fibrillation, Heart Failure, Diastolic Heart Failure
Interventions
Catheter ablation, Rate or Rhythm control antiarrhythmic drugs for atrial fibrillation, Insertion of CardioMems Hemodynamic monitor, Empiric heart failure drug therapy
Device · Drug
Lead sponsor
Electrophysiology Research Foundation
Other
Eligibility
18 Years to 75 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
7
States / cities
Flagstaff, Arizona • Jonesboro, Arkansas • Littleton, Colorado + 4 more
Completed No phase listed Observational Accepts healthy volunteers

UTSW HP [13-C] Pyruvate Injection in HCM

NCT03057002
Conditions
Cardiomyopathy, Hypertrophic, Dilated Cardiomyopathy, Duchenne Muscular Dystrophy, Cardiac Sarcoidosis, Becker Muscular Dystrophy, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction
Interventions
Hyperpolarized 13C-Pyruvate
Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Heart Failure NYHA Class IV
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
40,000 participants
Timeline
2019 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Diabetes Mellitus, Type 2, Heart Failure With Preserved Ejection Fraction (HFPEF)
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years and older
Enrollment
11,265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
AZD9977, Itraconazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Rate Adaptive Pacing
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Rochester, Minnesota • Kansas City, Missouri • Cincinnati, Ohio + 2 more
Enrolling by invitation Phase 1Phase 2 Interventional

Enhancing the Natriuretic Peptide System in HFpEF

NCT05279742
Conditions
Heart Failure With Preserved Ejection Fraction, Chronic Kidney Diseases
Interventions
MANP, Sacubitril/Valsartan, Oral Placebo, Injection Placebo
Drug
Lead sponsor
Horng Chen
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Recruiting No phase listed Observational Accepts healthy volunteers

Myocardial Mechanisms in Heart Failure With Preserved Ejection Fraction

NCT06517186
Conditions
Heart Failure, Heart Failure With Preserved Ejection Fraction
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
30 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
6
States / cities
Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 3 more
Conditions
Heart Failure
Interventions
Blood Sample, Stool Sample
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Heart Failure
Interventions
Placebo, Low Dose PF-07328948, Medium Dose PF-07328948, High Dose PF-07328948
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 79 Years
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
30
States / cities
Beverly Hills, California • Lake Forest, California • Santa Maria, California + 18 more
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Customized Sleep Coaching, Sleep Hygiene Training
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
STM01
Drug
Lead sponsor
Secretome Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
2
States / cities
Chicago, Illinois • Dallas, Texas
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
AZD4831, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 85 Years
Enrollment
711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
21
States / cities
Alexander City, Alabama • Little Rock, Arkansas • Sacramento, California + 18 more
Conditions
Pulmonary Hypertension, Diastolic Heart Failure, Heart Failure With Preserved Ejection Fraction
Interventions
Nebivolol
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Gainesville, Florida